Board summary
Key figures
64,811
Registered population
71.2% aged 18–64
10.8%
Aged 65+
ICB 14.9% · England 17.9%
51.5%
Ethnic minority (non-White)
23.4% Asian · England 9.6%
21.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~10,601
Core20 residents (est.)
Resident basis; registered basis ~13,799 · see page 3
6,841
Hypertension register
+1.34% in 3 yrs · England +5.60%
916
SMI register
9.7% of Manchester (LAD)'s
831
COPD register
Reviews +13.03% in 3 yrs
Forecast to 2030
7,604
Hypertension patients, 2030
+763 on today
68.5%
QRISK ≥20% on statins, 2030
+2.40pp over 3 yrs
3.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Core20 concentration spans 61.3 pp across practices.
Practice Core20 shares range from 6.8% at Chorlton Family Practice to 68.0% at Princess Road Surgery, although the PCN matches England at 21.2% (21.0%).
Hypertension control and SMI checks trail England.
Hypertension treatment to target is 61.6% (England 70.3%) and SMI blood pressure checks reach 76.9% (England 83.4%), which may reflect recall gaps.
Respiratory annual reviews exceed England despite register lags.
COPD annual reviews reach 79.5% (England 76.4%, up +13.0%) and asthma reviews reach 73.0% (England 65.7%), though recorded COPD prevalence fell 3.1%.
Population, age and ethnicity
A 71.2% working-age population and 51.5% non-White catchment may shape primary care demand
Across 64,811 registered patients, 71.2% are aged 18-64, above Manchester (68.9%), the ICB (63.3%) and England (62.7%), while 10.8% (6,986 patients) are aged 65+, above Manchester (9.6%) but below the ICB (14.9%) and England (17.9%). Non-White ethnic groups comprise 51.5% of associated Census residents, including 23.4% Asian and 14.3% Black groups, above Manchester (20.9% and 11.9%), the ICB (13.6% and 4.7%) and England (9.6% and 4.2%). Ethnicity reflects Census area residents rather than GP registers. List growth is projected at 4.5% to 2030 under an unverified methodology.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.9% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share matches England at 21.2% but practice shares span 61.3 pp
The PCN Core20 cohort is 21.2%, below Manchester (LAD) at 59.8% and NHS Greater Manchester ICB at 40.7%, but in line with England (21.0%). Practice shares span 61.3 pp, from 6.78% at Chorlton Family Practice to 68.04% at Princess Road Surgery (2,757 estimated patients) and 48.22% at The Range Medical Centre (7,234 estimated patients). Practice estimates sum to 13,799 registered patients, whereas the resident estimate is 10,601. Targeting must distinguish concentration from volume and reconcile resident and registered bases before deploying shared outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
916
SMI register
1.44% recorded prevalence
524
Learning disability register
0.82% recorded prevalence
17
Care homes, 349 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Recorded severe mental illness prevalence is 1.4% (916 patients), exceeding Manchester (1.3%), the ICB (1.1%) and England (1.0%). Learning disability register prevalence is 0.8% (524 patients), above Manchester (0.7%), the ICB (0.6%) and England (0.6%). The catchment contains 17 care homes (349 beds), though resident registrations are unconfirmed. With mental health and learning disability registers above England levels, systematic physical-health monitoring represents the priority workload to protect.
Severe mental illness: physical health checks
SMI recorded prevalence is 1.4% (England 1.0%). Annual physical checks trail benchmarks: 76.9% received a blood pressure check (England 83.4%) and 78.5% had a BMI recorded (England 82.1%). Local clinical audit would test recall pathways.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,841
Hypertension register
+1.34%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+3.62pp
BP control, under 80
≤140/90 · −0.92pp aged 80+
+763
More patients by 2030
Forecast 7,604 (11.02%)
Hypertension case-finding and control
Recorded hypertension prevalence is 10.7% (6,841 patients), below England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%) but similar to Manchester (LAD) (10.5%). Recent blood pressure checks reach 85.8% (England 90.0%). Blood pressure control to target is 61.6%, trailing Manchester (LAD) (67.7%), England (70.3%) and the ICB (71.4%), with under-80 control at 59.8% (England 67.8%) and aged 80+ at 71.7% (England 81.2%). This could reflect follow-up or titration gaps, which clinical audit would test. Trailing national and borough control benchmarks indicates scope to prioritise systematic blood pressure recall and treatment titration.
Lipids and statins
Lipid-lowering therapy reaches 63.4% of QRISK ≥ 20% patients (Manchester (LAD) 70.5%, England 63.6%) and 68.9% of CKD patients (Manchester (LAD) 77.4%, England 70.3%). Adult lipid-regulating prescribing is 1,630 items per 1,000 (England 4,100). Lower high-risk coverage than the borough indicates an opportunity to expand primary prevention through targeted lipid reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 86,559 | £1.90 | £1.94 | £1.86 | £164,462 |
| Cardiovascular (all), 2025 | 114,045 | £2.69 | £3.15 | £3.33 | £306,781 |
In 2026, lipid-regulating drug prescribing totaled 86,559 items at £1.90 per item (Manchester (LAD) £2.21, ICB £1.94, England £1.86), spending £3,462 more than at England's unit cost across 86,559 items; unit costs do not indicate treatment quality. Reviewing lipid-regulating drug prescribing may identify opportunities to align spend closer to national unit costs.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+4.38%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−3.14%
Asthma prevalence, PCN 3-yr % change
Annual reviews exceed England for COPD (79.5% vs 76.4%) and asthma (73.0% vs 65.7% across 4,248 patients), leaving about 1,100 asthma patients without a recorded review. Meanwhile, COPD recorded prevalence is 1.3% (831 patients) versus 1.9% in England, having fallen 3.1% from 2023 to 2025 (England +2.6%). Contracting registers alongside high review rates could reflect coding changes or list turnover, which case-finding audits would test.
Cancer register and children's immunisation
Cancer prevalence is 2.6% (1,689 patients), below England at 3.8%. Childhood immunisation coverage trails the 95.0% target. In the age-5 cohort, MMR dose 2 reaches 81.0%, trailing dose 1 (91.2%) by 10.2 pp, while the 4-in-1 booster reaches 74.1% (England 80.9%). Slower second-dose completion may reflect recall timing rather than refusal, which a cohort audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 2028 by 19.4 pp. Reaching 75% requires about 2,270 extra early-stage cases annually across the ICB; staging coverage was 70.8% (11,679 of 16,492). Locally, cervical screening is 62.0% (England 66.8%), falling 3.9% over 2023 to 2025 (England -1.0%), with lower uptake at Princess Road Surgery (42.8%) and The Range Medical Centre (49.2%). ICB figures cannot be attributed to PCN practices. Screening shortfalls at lower-uptake practices could delay early cancer detection across wider referral pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Cancer waits and diagnostics reflect acute trust performance rather than PCN delivery. For Jul 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% on the 62-day referral to treatment standard (standard 85.0%), compared with 74.7% at Stockport NHS Foundation Trust, 78.6% at Northern Care Alliance NHS Foundation Trust, 75.7% across NHS Greater Manchester Integrated Care Board, and 71.2% in England. On the 28-day faster diagnosis standard, Manchester University NHS Foundation Trust reached 80.1% (standard 75.0%). For diagnostics waiting 6+ weeks in Jul 2026, CT reached 14.7% (England 9.9%) and MRI reached 11.7% (England 21.4%).
| Pathways within standard (%) | Manchester | Northern Care Alliance | Stockport | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 83.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 97.39 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 74.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Stockport | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 1.41 | 21.40 |
| CT | 14.66 | 4.10 | 2.93 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 17.46 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 5.53 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.31 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 14.08 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), Manchester residents recorded 96,995 total contacts, of which 42,015 (43.3%) were with adults aged 65 and over. These borough-level community service figures describe broader local authority activity and cannot be attributed directly to PCN practices.
Practice variation and patient experience
Easy phone contact spans 38.0 pp across practices, which could reflect differing triage models
Across 2025/26, clinical QOF achievement reached 99.0% to 100.0% across captured practices (Princess Road Surgery 99.0%, Ashville Surgery 100.0%, Wilbraham Surgery 100.0%), against 97.1% in England. However, vaccination achievement spanned 84.4 pp, from 15.6% at Princess Road Surgery and Ashville Surgery to 100.0% at Wilbraham Surgery (England 55.2%). High clinical achievement does not ensure uniform immunisation delivery across lists.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Wilbraham Surgery | 88 | 6.8 | 69.3% | 58.6% | 92.6% |
| Alexandra | 92 | 13.6 | 81.1% | 72.4% | 92.3% |
| Ashville Surgery | 108 | 8.8 | 70.3% | 57.7% | 84.8% |
| Range | 68 | 48.2 | 60.7% | 87.1% | 76.3% |
| Chorlton | 111 | 6.8 | 43.1% | 65.9% | 73.3% |
| Princess Road | 102 | 68.0 | 59.0% | 66.8% | 70.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of twenty-five tracked three-year trends trail England, led by contracting disease registers
Across 25 tracked three-year trends from 2023 to 2025, 19 trail England. The sharpest relative lags are contractions in recorded QOF prevalence for learning disability (-12.8% versus +5.4% in England) and stroke (-8.7% versus +2.3%), alongside heart failure reviews, which fell 2.0% (England +8.7%). Mental health checks also slipped: BMI recording fell 3.0 pp (England +5.1 pp) and alcohol recording fell 0.7 pp (England +5.4 pp). Conversely, strengths outpaced national growth: COPD reviews rose +13.0% (England +2.8%) and smoking cessation offers increased +4.0 pp (England +0.1 pp) to reach 95.9%.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Stroke register
Heart failure reviews
BMI record (SMI)
Alcohol record (psychosis)
COPD reviews
Breast screening (53-70)
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (349 beds) | n/a | Schools (catchment) | 91 | n/a |
| Children's centres | 7 | 34 | Places of worship | 83 | 289 |
| Libraries | 4 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 15 | 68 | Primary academies | 8 | 50 |
| Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension control and case-finding audit
Across 6,841 hypertension patients (10.7% prevalence vs 15.2% England), blood pressure control is 61.6% vs 70.3% England; the unadjusted register gap is -28 to +3,030 patients. For discussion: run structured recall and medicines titration reviews for patients above target, alongside opportunistic blood pressure checks in high-Core20 practices. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
COPD case-finding and spirometry review
COPD prevalence is 1.3% (831 patients) vs 1.9% in Manchester (LAD) and England, falling 3.1% over 2023 to 2025 (England +2.6%); unadjusted gap is +377 to +397 patients. For discussion: audit records of smokers with repeated respiratory prescribing but no COPD code, and raise diagnostic spirometry capacity with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Asthma annual review recall
Asthma review coverage is 73.0% across 4,248 patients (7.1% prevalence), above England's 65.7%, leaving a scale indicator of 1,148 (about 1,100) unreviewed patients. For discussion: sustain review performance using a standardised recall template and flexible or after-school review slots alongside inhaler checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored access review (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage audit (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension control and case-finding audit (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · COPD case-finding and spirometry review (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
